HAL Portal Chu Clermont-Ferrand
Not a member yet
7589 research outputs found
Sort by
Acute simulated weight gain might not increase the energy cost of walking in adolescents with obesity
No full textInternational audienceSummary Introduction This work aims at evaluating the adaptations of the energy cost of walking (Cw) to simulated weight gain at different walking speeds in adolescents with obesity. Methods Substrate use and Cw were evaluated during a graded walking exercise (4 × 5min at 0.75, 1, 1.25, 1.5 m.s −1 ) performed under three randomized body weight conditions (BW‐conditions): (i) at the adolescents' body weight (BW + 0%) or with a simulated weight gain of (ii) 5%(BW + 5%) and (iii) 10%(BW + 10%), in 18 adolescents with obesity (14.2 ± 1.4 years, BMI:33.86 ± 2.55 kg.m‐ 2 ). Body composition was assessed by absorptiometry and perceived exertion rated after every walking speed stage. Results EE in absolute or relative to BW and FFM was different between BW‐conditions ( p = 0.017, 0.006 and 0.007, respectively) being lower on BW + 5% than BW + 10%. Gross Cw (absolute, relative to BW and fat‐free mass) showed overall speed ( p < 0.001) and BW‐conditions effects, being lower on BW + 5% compared with BW + 10% ( p < 0.001). Net Cw (absolute, relative to BW and fat‐free mass) showed a significant speed effect (<0.001) but no BW‐conditions nor interaction effect. Conclusion While EE and Cw have been shown to decrease in response to weight loss, potentially as a way to save stored energy and limit further weight loss, inverse adaptations do not seem to occur with increased acute simulated weight gain in weight stable adolescents with obesity
Evolution of bone mineral density after 5 years of TNF-alpha inhibitors in axial spondyloarthritis.
No full textInternational audienc
High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study
No full textInternational audienceAbstract Despite its indolent evolution, vitreoretinal lymphoma (VRL) has a poor prognosis due to a major risk of relapse in the central nervous system (CNS) and may necessitate aggressive therapy. However, the use of high-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT) is poorly documented. We retrospectively analysed from the French LOC network database the adult immunocompetent patients treated with HCT-ASCT for isolated VRL. Thirty-eight patients underwent consolidation with HCT-ASCT for isolated VRL between 2008 and 2019 after induction chemotherapy. Twenty patients had primary VRL, and 18 had an isolated VRL relapse of a primary CNS lymphoma. Three patients underwent HCT-ASCT in first-line treatment, 24 in second-line treatment, and 11 in subsequent lines. At HCT-ASCT, the median age was 61 years, and the median KPS was 90. Thirty-two patients (84%) received high-dose thiotepa-based HCT. One patient (3%) died from HCT-ASCT toxicity. Nineteen (50%) patients relapsed after HCT-ASCT, including 17 cases occurring in the brain. The median progression-free survival, brain-free survival and overall survival from HCT-ASCT were 96, 113 and 92 months, respectively. HCT-ASCT represents an effective therapeutic strategy for select VRL patients, with a tolerable safety profile. However, the risk of subsequent brain relapse remains significant
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry
No full textInternational audienc
Quel est l'impact des radiations ionisantes sur la fertilité masculine ?
No full textInternational audienc
A specific lipidomic signature associated to modification in skeletal muscle protein homeostasis during collagen-induced-arthritis in rats.
No full textInternational audienc
The t(X;20)(q13;q13) translocation is a good prognostic factor in myeloid neoplasms: A report of 25 cases from the Groupe Francophone de Cytogénétique Hématologique
No full textInternational audienc
Auditory Rehabilitation in Single-Sided-Deafened Patients after Surgery to the Cerebellopontine Angle for Vestibular Schwannoma: What Is the Patient’s Choice?
No full textInternational audienceBackground: Surgical resection of vestibular schwannomas (VS) can be responsible for single-sided deafness (SSD). Hearing restoration can be a challenge both for the otolaryngologist and the patient. Patients and Methods: In a retrospective series, we analyzed the charts of SSD patients operated on for VS from 2005–2021, checking which type of hearing rehabilitation was chosen. All patients who wanted a hearing restoration underwent a hearing in noise test (HINT) in a stereo auditorium with and without a bone-anchored hearing device (BAHD) worn with a headband on the deaf side. Then, they had a preimplantation one-month trial with the BAHD at home vs. contralateral routing of signal (CROS) or BiCROS (with contralateral signal amplification) hearing aids (HAs). Results: Among 52 charts of the included adult SSD patients, only 29 (56%) eventually chose a hearing rehabilitation device (14 BAHD). Only one BAHD patient required a device explantation for skin complications, but then asked for reimplantation. Another one swapped the BAHD for HAs 2.5 years after. Two patients only occasionally used their BAHD with a headband. Nine patients preferred HAs, mainly BiCROS. Their contralateral hearing was significantly less than BAHD patients (p < 0.05), and only three used their HAs every day. Conclusions: Hearing rehabilitation in SSD patients after VS surgical resection is chosen in about 50% of cases. In complement of HINT, a real-life comparative hearing trial helps patients chose the best device, with good long-term results when a BAHD is chosen. HAs are preferred when contralateral hearing is altered but are not always worn
Qu’est-ce que 2023 aura permis de changer dans nos pratiques en cancérologie ?
No full textInternational audienceIn 2023, the improvement of our therapeutic management has largely taken shape. The aim of our article is to highlight the major advances that will change our practices. These are not only in the field of treatment, but also in the improvement of supportive care. Here, we present these new developments organ by organ, cancer by cancer. You can read everything or concentrate on the cancers that are your areas of expertise. But this exhaustiveness should be representative of our current state of progress.L’amélioration de nos prises en charge thérapeutique s’est largement concrétisée en 2023. Notre article a pour but de faire émerger les avancées majeures, celles qui vont changer nos pratiques. Elles sont à la fois dans le domaine des traitements, mais également dans l’amélioration des prises en charge en termes de soins de support. Méthodiquement, nous proposons ici organe par organe, cancer par cancer, d’exposer ces nouveautés. Vous pourrez tout lire, ou bien, vous concentrer sur les cancers qui sont vos domaines d’expertise. Mais cette exhaustivité devrait être représentative de l’état actuel de nos avancées